<?xml version="1.0" encoding="UTF-8"?>
<p>Furthermore, both the exterior and interior of VLPs can be altered to enhance their stability and immunogenicity. Various adjuvants such as alum, CpG DNA, monophosphoryl lipid A (MPL), poly IC, gardiquimod, cholera toxin (CT) can be encapsulated into VLPs by exogenous and endogenous methods [
 <xref rid="B75-viruses-12-00518" ref-type="bibr">75</xref>,
 <xref rid="B76-viruses-12-00518" ref-type="bibr">76</xref>]. These adjuvanted VLPs show higher levels of antibodies in both sera and mucosa. In another study, adjuvants that stimulate TLR3 or NLPR3 pathways showed higher efficiency of influenza VLP vaccine in aged group of mice [
 <xref rid="B77-viruses-12-00518" ref-type="bibr">77</xref>]. The CpG-adjuvanted intranasal immunization with an egg-derived split H7N9 vaccine offered a high level of protection against H7N9 infection in mice [
 <xref rid="B78-viruses-12-00518" ref-type="bibr">78</xref>].
</p>
